Figure 3. Prophylactic vaccination with BAp peptide allows long-term survival in leukemic mice.

A. Naïve mice (N) were immunized with CFA+BAp, LM+BAp, LCMV+BAp or VSV+BAp. Secondary lymphoid organs were harvested at peak infection or two weeks post- immunization (CFA+BAp) and BAp:I-A^b-specific T cells were enumerated. More than two independent experiments are shown for each infection. Kruskal-Wallace and Dunn’s test used to establish significance. B. Percent Ly6C+ BAp:I-A^b-specific T cells from mice vaccinated with either LM+BAp or LCMV+BAp at d0 and then rechallenged with leukemia at d30. Two or more independent experiments with 4 or more replicates conducted for each infection. Mann-Whitney U Test used to establish significance. C. Mice were vaccinated with LCMV-Arm+/−BAp or VSV-I+/−BAp. >40 days later, mice were re-challenged with 2500 leukemic cells and survival assessed by Log-Rank (Mantel-Cox) test. Shown are three or more independent experiments with 8 or more replicates used for each group. D. 2500 BCR-ABL⁺ leukemic cells were adoptively transferred into control C57BL/6 mice or Ifng^−/− mice. Survival was analyzed using the Log-Rank (Mantel-Cox) test. E. Control C57BL/6 mice or Ifng^−/− mice were vaccinated with LCMV-Armstrong + BAp peptide and challenged with 2500 leukemic cells as in Figure 3B. Log-Rank (Mantel-Cox) test was used to establish significance. Shown are two or more independent experiments with 7 or more replicates used in each group.